CDC Opioid-Guideline Criticism and Public Comment Opportunity

An advocacy analysis challenges CDC/FDA evidence framing, MME-based risk interpretation, and applying overdose data directly to chronic-pain care. The Reagan-Udall public-comment period reportedly ends September 19, 2026; the opportunity may influence future policy discussion, though the article's broader claims require verification.